Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Shares Issued (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Shares Issued for 12 consecutive years, with $20000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Shares Issued changed N/A to $20000.0 in Q1 2025 year-over-year; TTM through Sep 2025 was -$256000.0, a 132.04% decrease, with the full-year FY2024 number at $99000.0, down 83.98% from a year prior.
  • Shares Issued was $20000.0 for Q1 2025 at Theravance Biopharma, up from -$276000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $484000.0 in Q2 2022 to a low of -$276000.0 in Q4 2024.
  • A 4-year average of $91000.0 and a median of $11500.0 in 2021 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 100.0% in 2021; the steepest drop was 100.0% in 2021.
  • Theravance Biopharma's Shares Issued stood at $3000.0 in 2021, then surged by 10366.67% to $314000.0 in 2022, then crashed by 187.9% to -$276000.0 in 2024, then skyrocketed by 107.25% to $20000.0 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Shares Issued are $20000.0 (Q1 2025), -$276000.0 (Q4 2024), and $314000.0 (Q4 2022).